使用视觉转换器在神经图像中检测阿尔茨海默病:系统性审查和元分析
Vivens Mubonanyikuzo1, Hongjie Yan2, Temitope Emmanuel Komolafe3
1College of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Journal of medical Internet research
|February 5, 2025
概括
视觉转换器 (ViT) 在从神经成像数据中检测阿尔茨海默病 (AD) 中显示出高准确度. 这一系统性审查证实了ViT的存在.
科学领域:
- 人工智能在医学中的应用
- 神经成像分析分析 神经成像分析
- 深度学习用于疾病诊断和诊断
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致认知能力下降.
- 视觉转换器 (ViT) 是先进的深度学习模型,具有医学图像分析的潜力.
- 在早期发现和诊断阿兹海默症方面,ViTs显示出前景.
研究的目的:
- 系统地审查应用ViTs用于AD检测的研究.
- 评估在AD中ViTs的诊断准确性.
- 评估网络架构对AD诊断的ViT性能的影响.
主要方法:
- 在主要数据库 (PubMed,科学网等) 进行系统的文献搜索. 从2020-2024年开始.
- 包括的研究使用了带有神经成像数据 (MRI,PET) 的ViT模型来检测AD.
- 使用随机效应模型对诊断准确度指标 (灵敏度,特异性,概率比) 的元分析.
主要成果:
- 对11项研究的元分析显示,在AD检测中,ViTs的综合诊断准确度很高.
- 灵敏度:0.925,特异性:0.957,AUC:0.924. 这是一个值.
- 维特显示出对准确和早期阿尔茨海默症诊断的巨大潜力.
结论:
- ViT模型有效地将AD患者与健康对照区分开来.
- 这次审查支持ViTs作为基于神经成像的AD诊断方法的有价值工具.
- 这些发现为人工智能驱动的AD诊断的未来进展提供了洞察力.
相关概念视频
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Vision
52.9K
Vision is the result of light being detected and transduced into neural signals by the retina of the eye. This information is then further analyzed and interpreted by the brain. First, light enters the front of the eye and is focused by the cornea and lens onto the retina—a thin sheet of neural tissue lining the back of the eye. Because of refraction through the convex lens of the eye, images are projected onto the retina upside-down and reversed.
52.9K
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158


